Parkinson's Disease Neuroprotection Clinical Trial

帕金森病神经保护临床试验

• 批准号: 6797316
• 负责人: GEORGE F WOOTEN
• 金额: $ 2.96万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6797316
• 关键词: Parkinson' s disease; chemoprevention; clinical research; cooperative study; human subject; human therapy evaluation; medical outreach /case finding; nervous system disorder chemotherapy; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): This is an application for a Clinical Center for the Parkinson's Disease Neuroprotection Trial from the Department of Neurology at the University of Virginia in response to RFA-NS-02-010. We have a clinical staff of four movement disorder subspeciality neurologists, a nurse coordinator, an administrative coordinator, and an information and referral coordinator. Over the past 10 years, our team has enrolled 445 subjects in clinical trials with 413 subjects completing the protocol. Our diagnostic accuracy and interrater reliability are documented objectively and are excellent. We have been highly productive of scholarly publications with 26-refereed publications on clinical aspects of PD in the past 5 years. Over the past six years we have ascertained 150 patients with a clinical diagnosis of Parkinson's disease (PD) who were receiving no symptomatic therapy. We have excellent alliances with multiple patient support groups and both referring neurologists and primary care physicians throughout the state of Virginia. Our team is experienced, productive, and fully able to meet the requirements to become a Clinical Cente for the Parkinson's Disease Neuroprotection Trial.

描述（由申请人提供）：这是弗吉尼亚大学神经病学系针对 RFA-NS-02-010 向帕金森病神经保护试验临床中心提出的申请。我们拥有由四名运动障碍亚专科神经科医生、一名护士协调员、一名行政协调员以及一名信息和转诊协调员组成的临床工作人员。在过去的 10 年里，我们的团队已招募了 445 名受试者参加临床试验，其中 413 名受试者完成了方案。我们的诊断准确性和评估者间的可靠性得到客观记录，并且非常出色。在过去 5 年里，我们在 PD 临床方面发表了 26 篇经参考的学术出版物，成果丰硕。在过去的六年里，我们已经确定了 150 名临床诊断为帕金森病 (PD) 且未接受对症治疗的患者。我们与弗吉尼亚州的多个患者支持团体以及转诊神经科医生和初级保健医生建立了良好的联盟。我们的团队经验丰富、富有成效，完全能够满足成为帕金森病神经保护试验临床中心的要求。